Teknova(US:TKNO)2022-02-21 12:01Company Overview - Teknova is a leading provider of research and clinical-grade reagents, supporting drug therapies, vaccines, and diagnostics[7] - The company has a strong competitive position with expertise in custom reagent manufacturing and short turnaround times[7] - Teknova produces bioprocessing tools critical to cell & gene therapy, creating a breakthrough growth opportunity[7] - The company has infrastructure in place to support growth, including investments in capacity expansion, marketing, sales, and R&D[8] - As of September 30, 2021, Teknova's TTM core revenue was $33.4 million with 37% TTM core growth, excluding $3.6 million of non-recurring Sample Transport revenue[9] - Clinical (GMP) TTM growth was 71%[9] Cell & Gene Therapy Market - The global Cell & Gene therapy market is expected to grow from $2.3 billion in 2020 to $45.4 billion in 2026, representing a 64% CAGR[31] - Teknova's portfolio addresses complex needs across the gene therapy production workflow[32] - Teknova is already a supplier to more than 65 leading Cell & Gene therapy organizations[41] Financial Performance - Total revenue increased by 41% year-over-year[54] - Total revenue of $33.4 million, excluding Sample Transport, increased by 37% year-over-year[54] - Clinical Solutions growth was strong, up 71% year-over-year[54]